MX2019005769A - Formulaciones farmaceuticas. - Google Patents
Formulaciones farmaceuticas.Info
- Publication number
- MX2019005769A MX2019005769A MX2019005769A MX2019005769A MX2019005769A MX 2019005769 A MX2019005769 A MX 2019005769A MX 2019005769 A MX2019005769 A MX 2019005769A MX 2019005769 A MX2019005769 A MX 2019005769A MX 2019005769 A MX2019005769 A MX 2019005769A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- pharmaceutically acceptable
- magl
- inhibitor
- acceptable salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 abstract 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se proporcionan formulaciones farmacéuticas que comprenden un inhibidor de la lipasa de monoacilglicerol (MAGL), o una de sus sales farmacéuticamente aceptables, y al menos un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423124P | 2016-11-16 | 2016-11-16 | |
US201762545857P | 2017-08-15 | 2017-08-15 | |
PCT/US2017/061871 WO2018093950A1 (en) | 2016-11-16 | 2017-11-15 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019005769A true MX2019005769A (es) | 2019-12-05 |
Family
ID=62145826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005769A MX2019005769A (es) | 2016-11-16 | 2017-11-15 | Formulaciones farmaceuticas. |
Country Status (23)
Country | Link |
---|---|
US (1) | US11273159B2 (es) |
EP (1) | EP3541385A4 (es) |
JP (1) | JP2020500176A (es) |
KR (1) | KR20190085046A (es) |
CN (1) | CN110290791A (es) |
AU (1) | AU2017361254B2 (es) |
BR (1) | BR112019009992A2 (es) |
CA (1) | CA3043609A1 (es) |
CL (1) | CL2019001337A1 (es) |
CO (1) | CO2019005070A2 (es) |
DO (1) | DOP2019000123A (es) |
EC (1) | ECSP19035322A (es) |
IL (1) | IL266522B2 (es) |
JO (1) | JOP20190108B1 (es) |
MA (1) | MA46867A (es) |
MX (1) | MX2019005769A (es) |
NI (1) | NI201900052A (es) |
PE (1) | PE20190919A1 (es) |
PH (1) | PH12019501076A1 (es) |
TN (1) | TN2019000148A1 (es) |
UA (1) | UA124884C2 (es) |
WO (1) | WO2018093950A1 (es) |
ZA (1) | ZA201903101B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107982266B (zh) | 2012-01-06 | 2021-07-30 | H.隆德贝克有限公司 | 氨基甲酸酯化合物及其制备和使用方法 |
US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
PT3541807T (pt) | 2016-11-16 | 2021-12-09 | H Lundbeck As | Uma forma cristalina de um inibidor de magl |
JOP20190108B1 (ar) | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
FI3630744T3 (fi) | 2017-05-23 | 2023-03-21 | H Lundbeck As | MAGL:n pyratsoli-inhibiittoreita |
MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
WO2021214550A1 (en) * | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
WO2023183900A1 (en) * | 2022-03-25 | 2023-09-28 | Nimbus Lakshmi, Inc. | Tyk2 inhibitor formulations and methods of making the same |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
SK279589B6 (sk) | 1991-11-22 | 1999-01-11 | Procter And Gamble Pharmaceuticals | Farmaceutický prípravok s retardovaným uvoľňovaním |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
ATE223704T1 (de) | 1992-10-16 | 2002-09-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von wachsmatrizes |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
WO2002049645A1 (en) | 2000-12-18 | 2002-06-27 | Novartis Ag | Therapeutic combination of amlodipine and benazepril |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
ES2319886T3 (es) | 2002-02-20 | 2009-05-14 | Abbott Laboratories | Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1). |
US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
AU2006318349B2 (en) * | 2005-11-28 | 2010-08-19 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
EP1938804A1 (en) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
CN107982266B (zh) * | 2012-01-06 | 2021-07-30 | H.隆德贝克有限公司 | 氨基甲酸酯化合物及其制备和使用方法 |
CA2866302A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
US9321750B2 (en) | 2012-04-20 | 2016-04-26 | Innov17 Llc | ROR modulators and their uses |
NZ745659A (en) * | 2012-11-02 | 2020-04-24 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
WO2015003002A1 (en) * | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
MX2017011997A (es) | 2015-03-18 | 2018-05-28 | Abide Therapeutics Inc | Carbamatos de piperacina y metodos de preparacion y uso. |
US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
PT3541807T (pt) | 2016-11-16 | 2021-12-09 | H Lundbeck As | Uma forma cristalina de um inibidor de magl |
JOP20190108B1 (ar) | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
-
2017
- 2017-11-15 JO JOP/2019/0108A patent/JOP20190108B1/ar active
- 2017-11-15 MA MA046867A patent/MA46867A/fr unknown
- 2017-11-15 JP JP2019523588A patent/JP2020500176A/ja active Pending
- 2017-11-15 MX MX2019005769A patent/MX2019005769A/es unknown
- 2017-11-15 US US16/349,042 patent/US11273159B2/en active Active
- 2017-11-15 UA UAA201905622A patent/UA124884C2/uk unknown
- 2017-11-15 CA CA3043609A patent/CA3043609A1/en active Pending
- 2017-11-15 PE PE2019001016A patent/PE20190919A1/es unknown
- 2017-11-15 KR KR1020197017143A patent/KR20190085046A/ko active IP Right Grant
- 2017-11-15 CN CN201780083650.9A patent/CN110290791A/zh active Pending
- 2017-11-15 WO PCT/US2017/061871 patent/WO2018093950A1/en active Application Filing
- 2017-11-15 BR BR112019009992A patent/BR112019009992A2/pt unknown
- 2017-11-15 TN TNP/2019/000148A patent/TN2019000148A1/en unknown
- 2017-11-15 EP EP17872562.8A patent/EP3541385A4/en active Pending
- 2017-11-15 AU AU2017361254A patent/AU2017361254B2/en active Active
-
2019
- 2019-05-08 IL IL266522A patent/IL266522B2/en unknown
- 2019-05-15 PH PH12019501076A patent/PH12019501076A1/en unknown
- 2019-05-16 NI NI201900052A patent/NI201900052A/es unknown
- 2019-05-16 CL CL2019001337A patent/CL2019001337A1/es unknown
- 2019-05-16 DO DO2019000123A patent/DOP2019000123A/es unknown
- 2019-05-17 ZA ZA201903101A patent/ZA201903101B/en unknown
- 2019-05-17 EC ECSENADI201935322A patent/ECSP19035322A/es unknown
- 2019-05-17 CO CONC2019/0005070A patent/CO2019005070A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3043609A1 (en) | 2018-05-24 |
AU2017361254B2 (en) | 2021-09-23 |
NI201900052A (es) | 2019-10-30 |
IL266522B2 (en) | 2023-07-01 |
EP3541385A4 (en) | 2020-06-24 |
EP3541385A1 (en) | 2019-09-25 |
PH12019501076A1 (en) | 2019-08-19 |
NZ753526A (en) | 2021-03-26 |
DOP2019000123A (es) | 2019-09-30 |
JP2020500176A (ja) | 2020-01-09 |
AU2017361254A1 (en) | 2019-06-06 |
CL2019001337A1 (es) | 2019-10-04 |
UA124884C2 (uk) | 2021-12-08 |
MA46867A (fr) | 2019-09-25 |
BR112019009992A2 (pt) | 2019-08-27 |
ZA201903101B (en) | 2020-11-25 |
IL266522A (en) | 2019-07-31 |
WO2018093950A1 (en) | 2018-05-24 |
RU2019116688A (ru) | 2020-12-17 |
IL266522B1 (en) | 2023-03-01 |
CN110290791A (zh) | 2019-09-27 |
TN2019000148A1 (en) | 2020-10-05 |
US20200188393A1 (en) | 2020-06-18 |
ECSP19035322A (es) | 2019-05-31 |
US11273159B2 (en) | 2022-03-15 |
JOP20190108B1 (ar) | 2023-09-17 |
CO2019005070A2 (es) | 2019-05-31 |
PE20190919A1 (es) | 2019-06-26 |
KR20190085046A (ko) | 2019-07-17 |
JOP20190108A1 (ar) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501076A1 (en) | Pharmaceutical formulations | |
PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
EP4045480A4 (en) | PHARMACEUTICAL FORMULATIONS | |
MX2017016802A (es) | Formulaciones farmaceuticas. | |
PH12016501825B1 (en) | Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same | |
ZA202006570B (en) | Pharmaceutical formulations | |
IL285674A (en) | Pharmaceutical formulations | |
MX2018005358A (es) | Comprimido de dosis alta que contiene mesalazina optimizado. | |
IN2013MU01985A (es) | ||
IN2013MU03370A (es) | ||
SG11202010792TA (en) | Improved pharmaceutical formulations | |
EA201991085A1 (ru) | Фармацевтические составы | |
EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
CR20190240A (es) | Formulaciones farmaceuticas | |
IN2013MU02015A (es) | ||
IN2014MU00077A (es) | ||
GB201909815D0 (en) | Active placebo system | |
ZA202212663B (en) | Pharmaceutical formulations | |
IL308250A (en) | Pharmaceutical formulations | |
GB202112820D0 (en) | Pharmaceutical formulations | |
EP3746080A4 (en) | PHARMACEUTICAL FORMULATIONS | |
GB202005282D0 (en) | Pharmaceutical Formulations | |
GB202003108D0 (en) | Pharmaceutical formulations | |
JOP20170198A1 (ar) | صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين | |
EP3661486A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF TETROFOSMINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: I-MAB BIOPHARMA US LIMITED |